{"id":761166,"date":"2023-06-01T08:04:44","date_gmt":"2023-06-01T12:04:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/"},"modified":"2023-06-01T08:04:44","modified_gmt":"2023-06-01T12:04:44","slug":"equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/","title":{"rendered":"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences"},"content":{"rendered":"

<\/p>\n

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences<\/b><\/p>\n

LA JOLLA, Calif.–(BUSINESS WIRE<\/a>)–
\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference.<\/p>\n

\nManagement will provide an overview of the Company\u2019s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be available for one-on-one meetings during both conferences.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Conference:<\/b><\/p>\n<\/td>\n

\n\n

\nLD Micro Invitational Conference<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\n\n

\nLuxe Hotel, Los Angeles<\/p>\n<\/td>\n<\/tr>\n

\n

Date:<\/b><\/p>\n<\/td>\n

\n\n

\nWednesday, June 7<\/p>\n<\/td>\n<\/tr>\n

\n

Time:<\/b><\/p>\n<\/td>\n

\n\n

\n11:30 am Pacific Time | 2:30 pm Eastern Time<\/p>\n<\/td>\n<\/tr>\n

The presentation at the LD Micro conference will be live-streamed on the event website at https:\/\/ldinv13.sequireevents.com\/<\/a>.<\/td>\n<\/tr>\n
\n\n\u00a0<\/td>\n<\/tr>\n
\n

Conference:<\/b><\/p>\n<\/td>\n

\n\n

\nJefferies Global Healthcare Conference<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\n\n

\nMarriott Marquis, New York City<\/p>\n<\/td>\n<\/tr>\n

\n

Date:<\/b><\/p>\n<\/td>\n

\n\n

\nFriday, June 9<\/p>\n<\/td>\n<\/tr>\n

\n

Time:<\/b><\/p>\n<\/td>\n

\n\n

\n7:30 am Pacific Time | 10:30 am Eastern Time<\/p>\n<\/td>\n<\/tr>\n

Webcast access for the Jefferies conference will be available on the Events & Presentations<\/a> page under the Investor Relations tab on the Company\u2019s website. An archived replay of the Jefferies conference will be available for 90 days.<\/td>\n<\/tr>\n<\/table>\n

About Equillium<\/b><\/p>\n

\nEquillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company\u2019s pipeline consists of the following novel first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101: a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ102: a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21; currently under evaluation in a Phase 1 first-in-human clinical study to include healthy volunteers and celiac disease patients. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and a Phase 1b clinical study of patients with lupus\/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd. for the development and commercialization of itolizumab under an option and asset purchase agreement.<\/p>\n

\nFor more information, visit www.equilliumbio.com<\/a>.<\/p>\n

Forward Looking Statements<\/b><\/p>\n

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, \u201ccould\u201d, \u201ccontinue\u201d, “expect”, “estimate”, \u201cmay\u201d, “plan”, “outlook”, \u201cfuture\u201d and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium\u2019s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium\u2019s ability to execute its plans and strategies; risks related to performing clinical studies; and whether the results from clinical studies will validate and support the safety and efficacy of Equillium\u2019s product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in Equillium’s filings and reports, <\/i>which may be accessed for free by visiting the Securities and Exchange Commission\u2019s website at <\/i>www.sec.gov<\/a><\/i> and on <\/i>Equillium\u2019s<\/i> website under the heading \u201cInvestors.\u201d <\/i>Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions<\/i>. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230601005179\/en\/<\/a><\/span><\/p>\n

Investor Contact
\n<\/b>
Michael Moore
\n
Vice President, Investor Relations & Corporate Communications
\n
619-302-4431
\n
ir@equilliumbio.com<\/a><\/p>\n

KEYWORDS:<\/b> California New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases Clinical Trials Stem Cells Biotechnology General Health Pharmaceutical Health Science Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences LA JOLLA, Calif.–(BUSINESS WIRE)– Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference. Management will provide an overview of the Company\u2019s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be available for one-on-one meetings during both conferences. Conference: LD Micro Invitational Conference Location: … <\/p>\n

Continue reading “Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-761166","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEquillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences LA JOLLA, Calif.–(BUSINESS WIRE)– Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference. Management will provide an overview of the Company\u2019s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be available for one-on-one meetings during both conferences. Conference: LD Micro Invitational Conference Location: … Continue reading "Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-01T12:04:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences\",\"datePublished\":\"2023-06-01T12:04:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/\"},\"wordCount\":746,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/\",\"name\":\"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-06-01T12:04:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences - Market Newsdesk","og_description":"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences LA JOLLA, Calif.–(BUSINESS WIRE)– Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference. Management will provide an overview of the Company\u2019s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be available for one-on-one meetings during both conferences. Conference: LD Micro Invitational Conference Location: … Continue reading \"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-01T12:04:44+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences","datePublished":"2023-06-01T12:04:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/"},"wordCount":746,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/","name":"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-06-01T12:04:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230601005179r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-jefferies-global-healthcare-ld-micro-invitational-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=761166"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761166\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=761166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=761166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=761166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}